Our group could recently confirm the efficacy of entinostat to block tumour growth and enhance chemosensitivity in PM and small cell lung cancer (SCLC), which in PM was clearly linked to interference with YB-1 acetylation [9, 34]. Here, YBX1 is linked to neoplasm.